Arcus Biosciences (RCUS) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Arcus Biosciences (RCUS) is Neutral.

The composite score behind that read is -0.06, weighing +0.17 of bullish evidence against -0.30 bearish.

Arcus Biosciences last closed at $24.41, +2.43% on the session.

Against the IVW growth benchmark the position is +1.63% over the forecast window.

The read is built from 15 underlying insights — 4 bullish and 11 bearish.

Agreement across those insights is 73%.

6 graded predictions for RCUS so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Arcus Biosciences in the 12th percentile on return on equity, where 100 is best.

Arcus Biosciences is classified under Health Care / Biotechnology, with a market capitalisation of $3.03B.

StockMap tracks Arcus Biosciences as the 70th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Arcus Biosciences ranks 174th of 381 in the group, against a group median of -0.08.